BMY
Bristol-Myers Squibb Company
NYSE · Healthcare · Drug Manufacturers - General · US
$66.82
−1.87%Jun 11, 2026, 11:03 UTC
Takeda Pharmaceutical announced that its experimental once-daily psoriasis pill outperformed Bristol Myers Squibb's Sotyktu in a late-stage head-to-head trial.
Source:Jun 11, 2026, 01:52 UTC
Harbour BioMed appointed Dr. Luisa Salter-Cid as Scientific Advisor.
Source:Jun 4, 2026, 16:55 UTC
Arcus Biosciences and Bristol Myers Squibb have formed a partnership to advance clinical studies of casdatifan combinations for kidney cancer.
Source:Jun 2, 2026, 18:01 UTC
Bristol Myers Squibb announced an update on the label expansion review for Camzyos in the EU.
Source:Jun 2, 2026, 18:01 UTC
Bristol Myers Squibb secured EU approval for Opdivo plus AVD in newly diagnosed advanced classical Hodgkin lymphoma.
Source:Jun 1, 2026, 10:59 UTC
The U.S. FDA accepted for priority review Bristol Myers Squibb's supplemental new drug application for Camzyos to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
Source:Jun 1, 2026, 10:55 UTC
The European Commission approved Bristol Myers Squibb's Opdivo in combination with AVD for previously untreated Stage III or IV classical Hodgkin Lymphoma.
Source:
← PreviousPage 2